Hims & Hers' stock fell sharply in early trading on Tuesday after the telehealth company reported a first-quarter net loss of $92 million and issued weaker-than-expected earnings guidance for the year.
The decline marked a 16% drop in the firm's share price, reflecting investor concerns over the company's financial performance and future prospects.
For instance, Shake Shack's stock had previously dropped 30% after a similar earnings miss and guidance cut.
The firm had previously announced a partnership with Novo Nordisk in March to sell the GLP-1 weight loss drug Wegovy on its platform.
However, the recent earnings report appears to have overshadowed that development, with analysts and investors reacting negatively to the financial shortfall and revised outlook.
This move follows a broader pattern of market reactions to companies missing earnings expectations.
For instance, Shake Shack's stock had previously dropped 30% after a similar earnings miss and guidance cut.